NCT06787781View on ClinicalTrials.gov

Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

June 1, 2021

Study Completion Date

December 31, 2021

Conditions
Metabolic EvaluationCardiac Complications
Interventions
DRUG

Alpha Lipoic Acid

ALA was administrated in capsules at a xed oral daily dose of 600 mg for the entire duration of the study in addition to the atypical antipsychotic therapy.

Trial Locations (1)

98122

University of Messina, Messina

All Listed Sponsors
lead

University of Messina

OTHER